Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- Google+
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Media

Corporate Communications

Here you can find a variety of information:

Our Corporate Communications team can be reached at pr-fre@fresenius.com.

“A pharmacy today? We need to expand it or add something new to it.” (Dr. Eduard Fresenius, Founder, 1912)

NEXT EVENT

February 20, 2020 | Bad Homburg, Germany

Conference Call Full Year Results 2019, Fresenius

Live Webcast

Import (ICS)

NEXT EVENT
NEXT EVENT

February 20, 2020 - 10:00 AM | Bad Homburg, Germany

Press Conference Full Year Results 2019, Fresenius and Fresenius Medical Care

Webcast

Import (ICS)

NEXT EVENT

News

Brief News
Fresenius Kabi enters into joint venture to advance new cell and gene therapies

Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No financial terms were disclosed.

January 21, 2020Fresenius Kabi

Brief News
Fresenius Helios trains doctors in antibiotics management

Fresenius Helios has started training experts in antibiotics management to combat the growing threat from multi-resistant bacteria. In the coming years, more than 600 doctors will be trained at the company’s 86 hospitals in Germany on the correct way to handle antibiotics. These doctors will raise awareness of the problem among colleagues and be available for consultations with them. In addition, Fresenius Helios is introducing a system under which each hospital will report on its antibiotics usage.

January 16, 2020Fresenius Helios
Fresenius successfully places bonds with a volume of 750 million euros

January 07, 2020Fresenius

Fresenius Helios acquires leading private hospital in Colombia

December 23, 2019Fresenius Helios
Dr. Karl Schneider retiring from Supervisory Board of Fresenius Management SE and named honorary member

December 19, 2019Fresenius

Brief News
Fresenius Helios awards new innovation prize

Fresenius Helios has awarded its inaugural Helios-Pro-Inno Prize for outstanding innovation and projects in patient care and hospital management. Three different projects at Helios Wuppertal, Helios Berlin-Buch and Helios Bad Saarow hospitals in Germany were honored: A color and lighting concept that demonstrably improved the well-being of intensive care patients and even reduced their need for certain medications; the appointment of a “Feel Good Manager” for resolving employees’ problems in the workplace, and an antibiotics reporting system developed in response to the growing threat from multi-resistant bacteria. A jury of eight members, from different occupational groups, chose the Helios-Pro-Inno Prize winners from more than 70 entries.

December 10, 2019Fresenius Helios
Fresenius Medical Care places bonds with a volume of 1.75 billion euros

November 20, 2019Fresenius Medical Care

Brief News
Fresenius Vamed completes main university hospital building in Lübeck

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Lübeck. Following the opening in August of the new main building at the UKSH’s other location, in Kiel, the modernization of Germany’s second-largest university hospital is now largely complete. In addition to the new construction and the comprehensive renovation of the two university hospital locations, the project includes their technical management through 2044. With a total volume of €1.7 billion, the UKSH modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

November 12, 2019Fresenius Vamed
Brief News
Fresenius Vamed wins awards for spa and wellness facilities

VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2019” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Spa Villas, St. Martins Therme & Lodge, Therme Laa Hotel & Spa and la pura women’s health resort – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria.

November 05, 2019Fresenius Vamed

Fresenius Helios acquires medical diagnostics provider in Colombia

November 04, 2019Fresenius Helios
Brief News
Fresenius Medical Care launches connected health platform in North America

Fresenius Medical Care North America (FMCNA) has launched its new connected health platform called TheHub. The platform is comprised of three integrated applications - PatientHub, CareTeamHub and ProviderHub - that enable patients, care teams, and providers to better collaborate and monitor patient treatments. Research by FMCNA indicates that patients who actively use these connected health solutions have a 20 percent lower risk of hospitalization, higher transplantation rates, and stay on the modality longer.

November 04, 2019Fresenius Medical Care

Brief News
Fresenius Medical Care North America achieves strongest quality ratings to date

Fresenius Medical Care North America continues to improve clinical quality as measured by the U.S. government’s Five-Star Rating System. More than 94 percent of the company’s dialysis centers were rated three stars and above for clinical quality, with a total of 762 centers achieving the highest five star rating, up from 658 last year. The Centers for Medicare and Medicaid Services (CMS) assigns one to five stars to each dialysis center annually based on a series of measurements around clinical performance and patient outcomes.

November 01, 2019Fresenius Medical Care
Fresenius confirms guidance after solid third quarter

October 29, 2019Fresenius

Fresenius Medical Care again delivers strong organic growth in the third quarter

October 29, 2019Fresenius Medical Care
Fresenius Medical Care appoints Dr. Frank Maddux to Management Board, makes Global Chief Medical Officer a board position

October 29, 2019Fresenius Medical Care

Brief News
Fresenius Kabi expands plant in Brazil

Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

October 23, 2019Fresenius Kabi
Fresenius celebrates expansion of Bad Homburg headquarters

October 16, 2019Fresenius

Brief News
Fresenius Helios develops system to measure patient safety

Fresenius Helios has developed a new system for measuring patient safety, and is introducing it in all 86 Helios hospitals across Germany. The new system will complement the company’s existing quality management system and combine internationally established patient safety indicators with various indicators that Helios has developed through clinical practice. These include measurements on such indicators as false diagnoses, medication errors and patient falls. When Helios begins reporting the results next year, it will be the first German hospital operator to provide patient safety data that can be compared internationally.

September 18, 2019Fresenius Helios
Brief News
Fresenius Kabi opens research and development center for biosimilars in Switzerland

Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.

September 18, 2019Fresenius Kabi

Brief News
Fresenius SE & Co. KGaA included in Dow Jones Sustainability Index

Fresenius will be included in the Dow Jones Sustainability Index Europe (DJSI Europe) for the first time as from 23 September 2019. The selected companies must demonstrate continuous improvement with regard to sustainability and are assessed by analysts from asset manager RobecoSAM.

September 17, 2019Fresenius
Brief News
2020 DRG inflator for German hospitals set at 3.66%

The price increase for hospital services in Germany has been set at 3.66% for 2020. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 16, 2019Fresenius Helios

Brief News
Fresenius Helios launches digital portal for patients

Fresenius Helios patients in Germany can soon start accessing letters from their doctors, test results and other medical documents over an online platform – the Helios Patients Portal. This new portal can also be used to make appointments. The confidentiality of patient data is assured through the use of two-factor authentification. All 86 of the company’s hospitals, 126 medical care centers and eight prevention centers throughout Germany are being gradually linked to the Helios Patients Portal. The company is also developing a portal for doctors.

September 11, 2019Fresenius Helios
Fresenius Medical Care’s publishes annual medical report

September 09, 2019Fresenius Medical Care

Brief News
Fresenius Medical Care builds new laboratory in Mississippi

Spectra Laboratories, a wholly-owned subsidiary of Fresenius Medical Care North America, broke ground on a 200,000-square-foot (approx. 18,500 square meters) laboratory in Southaven, Mississippi yesterday. The project is expected to create more than 300 jobs over the next three years. Spectra Laboratories offers renal-specific laboratory services, using state-of-the-art equipment, automated specimen processing, and reporting applications. At Spectra’s new build-to-suit facility, employees will conduct comprehensive testing, analysis, and reporting to ensure the best possible outcomes for patients.

September 06, 2019Fresenius Medical Care
Fresenius Medical Care invests EUR 60 million in Unicyte

September 05, 2019Fresenius Medical Care

Fresenius Helios acquires two hospitals in Colombia

September 02, 2019Fresenius Helios
Fresenius Medical Care appoints Helen Giza as Chief Financial Officer

August 27, 2019Fresenius Medical Care

Brief News
Fresenius Vamed completes main university hospital building in Kiel

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Kiel. The completion marks the first milestone in the modernization of Germany’s second-largest university hospital, with the main building of the Lübeck location scheduled to open in November. The project includes new construction and the comprehensive renovation of the two university hospital locations, some 80 kilometers (50 miles) apart in Schleswig-Holstein state, and their technical management through 2044. With a total volume of €1.7 billion, the UKSH’s modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

August 20, 2019Fresenius Vamed
Brief News
Fresenius Helios expands preventive medicine offering

Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.

August 05, 2019Fresenius Helios

Fresenius Medical Care on track to achieve full-year targets after solid second quarter

July 30, 2019Fresenius Medical Care

Disclaimer All news

Order Service News

Would you like to be included on our distribution list for media information? We would be happy to provide you with our latest press releases and brief news by e-mail. This service is free of charge and may be cancelled at any time.

Business & Finance

Medicine & Research

Brief News

German English

First name * Please enter your first name.

Last name * Please enter your lastname.

E-Mail Adress * Please enter your email-address.

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contact

Visit us